Clinical Articles

OBJECTIVE To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. METHODS We conducted a multicenter, phase II, randomized trial including patients with secondary progressive or relapsing-remitting MS, with a documented increase in the last year on the Expanded Disability Status Scale, in spite of conventional therapy, and presence of one or more gadolinium-enhancing (Gd+) areas. Patients were randomized to receive intense immunosuppression (mobilization with cyclophosphamide and filgrastim, conditioning with carmustine, cytosine-arabinoside, etoposide, melphalan, and anti-thymocyte globulin) followed by AHSCT or MTX 20 mg every month for 6 months. The primary endpoint was the cumulative number of new T2 lesions in the 4 years following randomization. Secondary endpoints were the cumulative number of Gd+ lesions, relapse rate, and disability progression. Safety and tolerability were also assessed. Twenty-one patients were randomized and 17 had postbaseline evaluable MRI scans. RESULTS AHSCT reduced by 79% the number of new T2 lesions as compared to MTX (rate ratio 0.21, p = 0.00016). It also reduced Gd+ lesions as well as the annualized relapse rate. No difference was found in the progression of disability. CONCLUSION Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS. These results strongly support further phase III studies with primary clinical endpoints.

As we age, stem cells lose efficacy and ability to heal.

Intravenous transplantation of bone marrow-derived mononuclear cells (BMMCs) successfully improved cognitive function and prevented neurodegeneration in two different Alzheimer's disease mouse models.

Current evidence points toward stem cell therapy as an effective treatment for human patients with DFU

This study illustrate that quality‐of‐life and functional capacity parameters improve with cell‐based therapy even if classic measures of cardiac function, such as ejection fraction, do not.

Clinical work has shared valuable data that confirm MSC effectiveness as an alternative cell source for cartilage repair.

Hematopoietic stem cell transplantation (HSCT) has been proposed as a therapeutic option for patients with Systemic Lupus Erythematosus (SLE) refractory to standard therapy. This therapeutic approach has been applied to other severe autoimmune diseases refractory to standard therapy with promising results.

In certain autoimmune diseases AHSCT can be good choice when conventional therapy failed.

Injection of imesenchymal stem cells directly into damaged spinal discs reduce back pain and help heal the disc tissue, potentially avoiding the need for surgery. This treatment works best when used early in disc problems and could help keep the spine working normally, preventing further damage and the need for more invasive procedures later.

Patients receiving MSCs saw significant improvement in standing and walking time, with reduced need for medication.

This study supports the benefit of intrathecal administration of autologous MSCs for the treatment of neuropathic pain in patients with spinal cord injuries.

All of the children demonstrated neurological improvement, with significant reductions in the number of both epileptic seizures and SE episodes, with an improved quality of life.